MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
暂无分享,去创建一个
A. Folgori | A. Nicosia | P. Klenerman | E. Novellino | Leo Swadling | E. Barnes | J. Christensen | F. Mori | M. Stornaiuolo | A. Thomsen | P. Holst | P. Cicconi | A. Lahm | Annette von Delft | M. R. Bassi | L. Dorrell | S. Colloca | S. Capone | C. Gentile | M. del Sorbo | I. Esposito | A. M. D’Alise | Anthony Brown | Marialuisa Esposito | V. Vassilev | Wenqin Li | T. Donnison | Bethany Turner | F. Barra | A. M. Contino | A. Abbate | F. Grazioli | V. Ammendola | L. Siani | A. D’Alise | A. Brown | Federica Barra
[1] H. McShane,et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial , 2019, PLoS medicine.
[2] A. Folgori,et al. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection , 2019, Front. Immunol..
[3] A. Hill,et al. Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses , 2018, Scientific Reports.
[4] D. Baeten,et al. Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort , 2018, Arthritis Research & Therapy.
[5] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.
[6] A. Hill,et al. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries , 2017, Journal of virus eradication.
[7] A. Hill,et al. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy , 2017, Oncotarget.
[8] B. Schröder. The multifaceted roles of the invariant chain CD74--More than just a chaperone. , 2016, Biochimica et biophysica acta.
[9] D. M. van der Heijde,et al. FRI0514 Adding Mri of The Spine To The Asas Classification Criteria for Axial Spondyloarthritis, Redundant or Beneficial? Data from The Spondyloarthritis Caught Early (Space)-Cohort , 2016 .
[10] M. Hellard,et al. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? , 2016, PloS one.
[11] M. Hellard,et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments , 2015, BMC Medicine.
[12] Mark M. Davis,et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.
[13] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[14] T. Hanke,et al. Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial , 2014, PloS one.
[15] A. Folgori,et al. Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain , 2014, PloS one.
[16] A. Folgori,et al. Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] A. Hill,et al. Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] B. Jensen,et al. Adenovirus-Based Vaccine against Listeria monocytogenes: Extending the Concept of Invariant Chain Linkage , 2013, The Journal of Immunology.
[19] Jonathan J Deeks,et al. Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.
[20] T. Matthias,et al. Autoantibodies against CD74 in spondyloarthritis , 2013, Annals of the rheumatic diseases.
[21] J. Braun,et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis , 2013, Annals of the rheumatic diseases.
[22] Todd M. Allen,et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence , 2012, The Journal of experimental medicine.
[23] A. Folgori,et al. Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species , 2012, Science Translational Medicine.
[24] A. Folgori,et al. Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.
[25] A. Hill,et al. CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria , 2011, The Journal of Immunology.
[26] P. Klenerman,et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection , 2011, Gut.
[27] J. Christensen,et al. Vaccination against Lymphocytic Choriomeningitis Virus Infection in MHC Class II-Deficient Mice , 2011, The Journal of Immunology.
[28] J. Bukh,et al. Enhanced and Sustained CD8+ T Cell Responses with an Adenoviral Vector-Based Hepatitis C Virus Vaccine Encoding NS3 Linked to the MHC Class II Chaperone Protein Invariant Chain , 2011, The Journal of Immunology.
[29] Mario Roederer,et al. SPICE: Exploration and analysis of post‐cytometric complex multivariate datasets , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[30] Raymond T Chung,et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. , 2011, Gastroenterology.
[31] A. Folgori,et al. Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.
[32] H. Pircher,et al. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T‐cell‐independent CD8+ T‐cell‐mediated tumor control , 2009, European journal of immunology.
[33] James O Lloyd-Smith,et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. , 2009, Epidemics.
[34] J. Christensen,et al. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. , 2009, The Journal of general virology.
[35] Viswanath Devanarayan,et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.
[36] J. Christensen,et al. MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines1 , 2008, The Journal of Immunology.
[37] P. Klenerman,et al. Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ TEMRA Cells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point , 2007, Journal of Virology.
[38] A. Folgori,et al. A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques , 2006, Journal of Virology.
[39] B. Chain,et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[40] A. Folgori,et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees , 2006, Nature Medicine.
[41] G. Pape,et al. Minimal T-Cell-Stimulatory Sequences and Spectrum of HLA Restriction of Immunodominant CD4+ T-Cell Epitopes within Hepatitis C Virus NS3 and NS4 Proteins , 2005, Journal of Virology.
[42] Todd M. Allen,et al. Broad Repertoire of the CD4+ Th Cell Response in Spontaneously Controlled Hepatitis C Virus Infection Includes Dominant and Highly Promiscuous Epitopes1 , 2005, The Journal of Immunology.
[43] Todd M. Allen,et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.
[44] P. S. Bennett,et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. , 2004, Human gene therapy.
[45] Charles M. Rice,et al. HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.
[46] R D Sturrock,et al. Ankylosing spondylitis and HL-A 27. , 1973, Lancet.
[47] C. Johnson. Progress and Prospects , 1991 .